C Diff Drug Development

C Diff Drug Development

976 bookmarks
Custom sorting
Recombinant Fusion Protein Vaccine Containing Clostridioides difficile FliC and FliD Protects Mice against C. difficile Infection - PubMed
Recombinant Fusion Protein Vaccine Containing Clostridioides difficile FliC and FliD Protects Mice against C. difficile Infection - PubMed
Bacterial flagella are involved in infection through their roles in host cell adhesion, cell invasion, auto-agglutination, colonization, the formation of biofilms, and the regulation and secretion of nonflagellar bacterial proteins that are involved in the virulence process. In this study, we constr …
·pubmed.ncbi.nlm.nih.gov·
Recombinant Fusion Protein Vaccine Containing Clostridioides difficile FliC and FliD Protects Mice against C. difficile Infection - PubMed
Mass General Brigham researchers find new ways to combat C. difficile
Mass General Brigham researchers find new ways to combat C. difficile
Mass General Brigham researchers at two hospitals found the metabolic strategies C. difficile uses to rapidly colonize the gut and identified ways to combat the disease
·beckershospitalreview.com·
Mass General Brigham researchers find new ways to combat C. difficile
GutMicrobiota Health on Twitter
GutMicrobiota Health on Twitter
This research represents a significant step for better elucidating the interaction between drugs and the gut microbiome:https://t.co/oE2z0BpxBm— GutMicrobiota Health (@GMFHx) March 14, 2023
·twitter.com·
GutMicrobiota Health on Twitter
Researchers uncover metabolic secrets of anaerobes and identify new strategies to treat c. difficile infections: Study offers possibilities for further understanding of microbial metabolites with findings applicable to clinical medicine
Researchers uncover metabolic secrets of anaerobes and identify new strategies to treat c. difficile infections: Study offers possibilities for further understanding of microbial metabolites with findings applicable to clinical medicine
A team of investigators has identified metabolic strategies used by Clostridioides difficile to rapidly colonize the gut. The findings identify methods to better prevent and treat the most common cause of antibiotic-associated diarrhea and healthcare-acquired infections (HAIs). The team's approach has implications for understanding broader aspects of microbial metabolism, including responses to antibiotics, and production of important metabolites.
·sciencedaily.com·
Researchers uncover metabolic secrets of anaerobes and identify new strategies to treat c. difficile infections: Study offers possibilities for further understanding of microbial metabolites with findings applicable to clinical medicine
Discontinuation of Postoperative Prophylactic Antibiotics for Endoscopic Endonasal Skull Base Surgery - PubMed
Discontinuation of Postoperative Prophylactic Antibiotics for Endoscopic Endonasal Skull Base Surgery - PubMed
Background Postoperative prophylactic antibiotic usage for endoscopic skull base surgery varies based on the institution as evidence-based guidelines are lacking. The purpose of this study is to determine whether discontinuing postoperative prophylactic antibiotics in endoscopic endonasal cas …
·pubmed.ncbi.nlm.nih.gov·
Discontinuation of Postoperative Prophylactic Antibiotics for Endoscopic Endonasal Skull Base Surgery - PubMed
Microbiome therapeutic offers ‘durable’ improvement in quality of life for recurrent CDI
Microbiome therapeutic offers ‘durable’ improvement in quality of life for recurrent CDI
Use of the investigational microbiome therapeutic SER-109 resulted in rapid and steady improvement in disease-specific quality of life for patients with recurrent Clostridioides difficile infection, according to data in JAMA Network Open.“C. diff infection is associated with poor quality of life (QOL), but improvement in QOL has never been demonstrated in randomized controlled
·news.google.com·
Microbiome therapeutic offers ‘durable’ improvement in quality of life for recurrent CDI
UK biotech hands off mid-stage C. difficile drug in up to $570M deal
UK biotech hands off mid-stage C. difficile drug in up to $570M deal
A biotech in the UK has out-licensed a C. difficile candidate to a US biotech for further clinical and commercialization efforts. UK-based Destiny Pharma announced Friday that it is handing NTCD-M3 to Sebela Pharmaceuticals. The deal includes an initial $1 million upfront, $19 million in development milestones, and an additional
·news.google.com·
UK biotech hands off mid-stage C. difficile drug in up to $570M deal
Microbial medics diagnose and treat gut inflammation
Microbial medics diagnose and treat gut inflammation
Engineered microbes show potential for diagnosing and treating diseases. In this issue of Cell Host & Microbe, Zou et al. develop an “intelligent” bac…
·sciencedirect.com·
Microbial medics diagnose and treat gut inflammation
Targeting the Impossible: A Review of New Strategies against Endospores
Targeting the Impossible: A Review of New Strategies against Endospores
Endospore-forming bacteria are ubiquitous, and their endospores can be present in food, in domestic animals, and on contaminated surfaces. Many spore-forming bacteria have been used in biotechnological applications, while others are human pathogens responsible for a wide range of critical clinical i …
·pubmed.ncbi.nlm.nih.gov·
Targeting the Impossible: A Review of New Strategies against Endospores
Non-Toxin-Based Clostridioides difficile Vaccination Approaches
Non-Toxin-Based Clostridioides difficile Vaccination Approaches
Clostridioides difficile (CD) is a Gram-positive, anaerobic bacterium that infects mainly hospitalized and elderly people who have been treated with long-term antibiotic therapy leading to dysbiosis. The deteriorating demographic structure and the increase in the number of antibiotics used in …
·pubmed.ncbi.nlm.nih.gov·
Non-Toxin-Based Clostridioides difficile Vaccination Approaches
Plant-Derived Products with Therapeutic Potential against Gastrointestinal Bacteria
Plant-Derived Products with Therapeutic Potential against Gastrointestinal Bacteria
The rising burden of antimicrobial resistance and increasing infectious disease outbreaks, including the recent COVID-19 pandemic, has led to a growing demand for the development of natural products as a valuable source of leading medicinal compounds. There is a wide variety of active constituents f …
·pubmed.ncbi.nlm.nih.gov·
Plant-Derived Products with Therapeutic Potential against Gastrointestinal Bacteria
The Urgent Threat of Clostridioides difficile Infection: A Glimpse of the Drugs of the Future, with Related Patents and Prospects
The Urgent Threat of Clostridioides difficile Infection: A Glimpse of the Drugs of the Future, with Related Patents and Prospects
Clostridioides difficile infection (CDI) is an urgent threat and unmet medical need. The current treatments for CDI are not enough to fight the burden of CDI and recurrent CDI (r-CDI). This review aims to highlight the future drugs for CDI and their related patented applications. The non-pate …
·pubmed.ncbi.nlm.nih.gov·
The Urgent Threat of Clostridioides difficile Infection: A Glimpse of the Drugs of the Future, with Related Patents and Prospects
Non-Toxin-Based Clostridioides difficile Vaccination Approaches
Non-Toxin-Based Clostridioides difficile Vaccination Approaches
Clostridioides difficile (CD) is a Gram-positive, anaerobic bacterium that infects mainly hospitalized and elderly people who have been treated with long-term antibiotic therapy leading to dysbiosis. The deteriorating demographic structure and the increase in the number of antibiotics used in …
·pubmed.ncbi.nlm.nih.gov·
Non-Toxin-Based Clostridioides difficile Vaccination Approaches
Bacteriophage discovery to advance biotechnology and biotherapeutics
Bacteriophage discovery to advance biotechnology and biotherapeutics
Nature Reviews Microbiology - This Genome Watch explores how large-scale microbiome studies are facilitating discoveries in bacteriophage biology and functional capabilities that are prime for...
·nature.com·
Bacteriophage discovery to advance biotechnology and biotherapeutics
C. difficile Clinical Study 19-0021: C. diff Clinical Trials
C. difficile Clinical Study 19-0021: C. diff Clinical Trials
Learn about our ongoing C. diff treatment trial: a randomized, double-blind evaluation of CRS3123 vs. Oral Vancomycin for adults with C. difficile Infection.
·crestonepharma.com·
C. difficile Clinical Study 19-0021: C. diff Clinical Trials